Yew Bio-Pharm Group, Inc.
YEWB · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $27,308 | $27,884 | $37,597 | $40,540 |
| % Growth | -2.1% | -25.8% | -7.3% | – |
| Cost of Goods Sold | $23,781 | $27,110 | $26,873 | $35,478 |
| Gross Profit | $3,527 | $774 | $10,724 | $5,062 |
| % Margin | 12.9% | 2.8% | 28.5% | 12.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $989 | $1,451 | $2,084 | $1,651 |
| SG&A Expenses | $989 | $1,451 | $2,084 | $1,737 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $87 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $989 | $1,451 | $2,084 | $1,737 |
| Operating Income | $2,569 | -$620 | $719 | $3,325 |
| % Margin | 9.4% | -2.2% | 1.9% | 8.2% |
| Other Income/Exp. Net | -$1,075 | -$15 | -$548 | -$111 |
| Pre-Tax Income | $1,494 | $997 | $171 | $3,214 |
| Tax Expense | $29 | $11 | $1,493 | $1 |
| Net Income | $1,465 | $986 | -$1,322 | $3,213 |
| % Margin | 5.4% | 3.5% | -3.5% | 7.9% |
| EPS | 0.03 | 0.02 | -0.025 | 0.06 |
| % Growth | 50% | 178.7% | -142.3% | – |
| EPS Diluted | 0.03 | 0.02 | -0.025 | 0.06 |
| Weighted Avg Shares Out | 51,700 | 51,761 | 51,965 | 51,875 |
| Weighted Avg Shares Out Dil | 51,700 | 51,761 | 51,965 | 53,934 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $482 | $390 | $294 | $225 |
| Depreciation & Amortization | $2,802 | $1,827 | $11,042 | $3,747 |
| EBITDA | $4,777 | $1,208 | $19,766 | $3,325 |
| % Margin | 17.5% | 4.3% | 52.6% | 8.2% |